Adults with Type II diabetes treated with Sanofi‘s (NYSE:SNY) Toujeo Gla-300 insulin glargine had better blood glucose stability than those treated with the company’s Lantus Gla-100 insulin glargine product, according to a study presented at the annual meeting of the European Association for the Study of Diabetes.
The analysis re-analyzed patient data from the Edition II and Edition III clinical trials, which included adults with Type II diabetes, as well as the Senior study, which enrolled elderly patients with Type II diabetes.
Study participants collected self-measured blood glucose data multiple times each day. The data were used to calculate glucose variability and were evaluated alongside hypoglycemia events reported during the studies.
The analysis showed statistically significant reductions in glucose variability and hypoglycemia risk with Toujeo compared to Lantus. The risk differences were most distinct overnight, the company reported.
“The analysis used an innovative risk-based measure, the Low Blood Glucose Index (LBGI), which was calculated using blood glucose level data collected during the studies. This metric was confirmed as a powerful predictor of documented symptomatic (< 3 mmol/L [54 mg/dL]) and severe hypoglycemia among the glycemic variability measures tested. Its clinical relevance lies in the fact that from simple self-measured blood glucose values, it can identify patients who are at high risk of hypoglycemia,” Boris Kovatchev, director of the University of Virginia Center for Diabetes Technology & professor at the University of Virginia School of Medicine, said in prepared remarks.
“Patients treated with Gla-300 achieved lower blood glucose variability and risk of documented symptomatic and severe hypoglycemia, confirmed by LBGI values, consistently in all three clinical trials. The hypoglycemia risk difference in favor of Toujeo was most evident during the night.”
“These data add to the consistent body of evidence around Gla-300, which includes a continuous glucose monitoring study and comparative observational studies like the Deliver program, in patients with Type II diabetes,” Riccardo Perfetti, Sanofi’s VP of global DCV medical affairs, added.